Company profile

Indapta Therapeutics, Inc.

Privately held: no public share price (Indapta Therapeutics is a privately held clinical-stage allogeneic NK-cell therapy company (South San Francisco), most recently closing a $22.5M round in Dec 2024 led by RA Capital/Leaps by Bayer/Vertex Ventures HC (businesswire.com, biospace.com). No public listing found. Sources: https://clinicaltrials.gov/study/NCT06119685 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
IDP-023
Phase 2
Allogeneic g-NK cell therapyCell therapy
Multiple MyelomaMultiple Sclerosis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.